Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 4/20 | 0.32 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.30 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13997318 | 0.82 | SUCNR1 (0.39) | MAPK1NPSR1CA2 | |
| SCHEMBL5048000 | 0.82 | SUCNR1 (0.39) | MAPK1NPSR1CA2 | |
| SCHEMBL26678742 | 0.82 | SUCNR1 (0.39) | MAPK1NPSR1CA2 | |
| SCHEMBL15514446 | 0.82 | SUCNR1 (0.39) | MAPK1NPSR1CA2 | |
| SCHEMBL14007051 | 0.82 | SUCNR1 (0.39) | MAPK1NPSR1CA2 | |
| SCHEMBL2898462 | 0.81 | CA2 (0.43) | MAPK1NPSR1CA2CA1CA9 | |
| SCHEMBL16153579 | 0.81 | CA2 (0.43) | MAPK1NPSR1CA2CA1CA9 | |
| SCHEMBL10070675 | 0.77 | CA1 (0.31) | CA2CA1CA9 | |
| SCHEMBL5028037 | 0.77 | CA2 (0.31) | CA2CA1CA9 | |
| SCHEMBL21302910 | 0.75 | CA2 (0.36) | CA2CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190263815-A1 | PROCESSES FOR PREPARING TPH1 INHIBITORS | ALTAVANT SCIENCES GMBH (CH) | 2019-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190263815-A1 | PROCESSES FOR PREPARING TPH1 INHIBITORS | TPH1, TPH2, HTR1A | MAPK1 808/4885NPSR1 247/4885CA2 4160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.